Global Rheumatology Therapeutics Market, By Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD’s), Nonsteroidal Anti-Inflammatory Drugs (NSAID’s), Corticosteroids, Uric Acid Drugs), Disease Indication (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
The rheumatology therapeutics market is expected to witness market growth at a rate of 2.23% in the forecast period of 2021 to 2028 and is expected to reach USD 39,463.29 million by 2028. Data Bridge Market Research report on rheumatology therapeutics market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of rheumatoid arthritis is escalating the growth of rheumatology therapeutics market.
Rheumatology refers to the discipline of internal medicine including the diagnosis and treatment of rheumatic diseases. Rheumatic diseases are defined as the inflammation that affects joints, tendons, ligaments, bones and sometimes organs. These diseases are also known as musculoskeletal disease causing severe pain, deformity and morbidity. The treatment tends to be highly expensive. Several types of rheumatic diseases with different symptoms are seen all across the world among all age groups.
The growth in awareness regarding the early diagnosis and treatment on symptoms of rheumatology disease and the increasing use of disease-modifying anti-rheumatic drugs (DMARD’s) for treatment of the respective disease act as the major factors driving the growth of rheumatology therapeutics market. The increasing prevalence of rheumatology diseases, rising trend for fitness across the globe and growing acceptance of biopharmaceuticals accelerate the rheumatology therapeutics market growth. The rising number of small molecules in the drug development pipeline as they are known to be less expensive than the biologics further influence the rheumatology therapeutics market. Additionally, growth in geriatric population, technological advancements in pharmaceutical sector, increasing investments in healthcare industry and surge in healthcare expenditure of mid-earing population positively affect the rheumatology therapeutics market. Furthermore, rise in the rate of launches of novel biologics drugs, increasing approvals and growing penetration of generic drugs extend profitable opportunities to the rheumatology therapeutics market players in the forecast period of 2021 to 2028.
On the other hand, high cost associated with the treatment and rising demand for biosimilar products are the factors expected to obstruct the rheumatology therapeutics market growth. The issues with the patent expiry of well-known drugs used in the treatment of rheumatology diseases are projected to challenge the rheumatology therapeutics market in the forecast period of 2021 to 2028.
This rheumatology therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on rheumatology therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Rheumatology Therapeutics Market Scope and Market Size
The rheumatology therapeutics market is segmented on the basis of drug class, disease indication and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of drug class, the rheumatology therapeutics market is segmented into disease modifying anti-rheumatic drugs (DMARD’s) and nonsteroidal anti-inflammatory drugs (NSAID’s).
- On the basis of disease indication, the rheumatology therapeutics market is segmented into rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis and ankylosing spondylitis.
- On the basis of distribution channel, the rheumatology therapeutics market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Global Rheumatology Therapeutics Market Country Level Analysis
The rheumatology therapeutics market is analyzed and market size insights and trends are provided by country, drug class, disease indication and distribution channel as referenced above.
The countries covered in the rheumatology therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the rheumatology therapeutics market due to the rise in the elderly population, adoption of biologics and biosimilars products for the treatment of moderate to severe rheumatoid arthritis and well-developed healthcare infrastructure. Asia-Pacific is expected to witness the highest growth rate during the forecast period of 2021 to 2028 because of the significant proportion of population suffering from rheumatoid arthritis and osteoarthritis, increasing approvals of biosimilars for the treatment of several types of rheumatology disorders and surge in per capita healthcare expenditure in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The rheumatology therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for rheumatology therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the rheumatology therapeutics market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Rheumatology Therapeutics Market Share Analysis
The rheumatology therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to rheumatology therapeutics market.
The major players covered in the rheumatology therapeutics market report are AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Amgen Inc., Novartis AG, Janssen Pharmaceuticals, Inc., Sanofi, Genentech, Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd, UCB S.A., Lilly, Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Rheumatology Therapeutics Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.